ASH Annual Meeting 2012—Chronic Myeloid Leukemia Update
memo - Magazine of European Medical Oncology2013Vol. 6(3), pp. 167–169
Citations Over Time
Related Papers
- → Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy(2011)55 cited
- → Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib(2014)20 cited
- → Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?(2010)12 cited
- → Strategies for overcoming imatinib resistance in chronic myeloid leukemia(2007)29 cited
- → NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib(2012)5 cited